Dalpiciclib partially abrogates ER signaling activation induced by pyrotinib in HER2+HR+ breast cancer

Dalpiciclib partially abrogates ER signaling activation induced by pyrotinib in HER2+HR+ breast cancer

Recent evidences from clinical trials (NCT04486911) revealed that the combination of pyrotinib, letrozole, and dalpiciclib exerted optimistic therapeutic effect in treating HER2+HR+ breast cancer; however, the underlying molecular mechanism remained elusive. Through the drug sensitivity test, the dr...

Full description

Bibliographic Details
Main Authors: Jiawen Bu, Yixiao Zhang, Nan Niu, Kewei Bi, Lisha Sun, Xinbo Qiao, Yimin Wang, Yinan Zhang, Xiaofan Jiang, Dan Wang, Qingtian Ma, Huajun Li, Caigang Liu
Format: Article
Language:English
Published: eLife Sciences Publications Ltd 2023-01-01
Series:eLife
Subjects:
breast cancer cell line
xenograft mouse model
patient specimens
Online Access:https://elifesciences.org/articles/85246

Internet

https://elifesciences.org/articles/85246

Similar Items